Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2-...

Related Keywords

San Antonio ,Texas ,United States ,France ,Spain ,Chicago ,Illinois ,Paris ,France General ,Switzerland ,Barcelona ,Comunidad Autonoma De Cataluna ,Lugano ,Ticino ,Norway ,American ,Fran Visco ,Dennisj Slamon ,Prnewswire Novartis ,Shreeram Aradhye ,Jonsson Comprehensive Cancer Center ,European Society For Medical Oncology ,Twitter ,American Society Of Clinical Oncology ,National Breast Cancer Coalition ,Drug Administration ,Global Drug Development ,Exchange Commission ,Akershus University Hospital ,American Cancer Society ,European Commission ,Steering Committee ,Novartis Pharmaceuticals Corporation ,Astex Pharmaceuticals ,Translational Research In Oncology ,Novartis Institutes For Biomedical Research ,Nj Novartis Pharmaceuticals Corporation ,American Society Of Clinical Oncology Annual Meeting ,Vestre Viken Hospital ,Clinical Translational Research ,European Society Of Medical Oncology Congress ,Pfizer Inc ,Novartis ,Clinical Oncology ,Multichannel News Release ,Translational Research ,Comprehensive Cancer Center ,Executive Director ,Chief Medical Officer ,Standardized Definitions ,Efficacy End Points ,Clinical Benefit Scale ,United States Food ,Novartis Institutes ,Biomedical Research ,Prescribing Information ,East Hanover ,Pharmaceuticals Corporation ,American Society ,Clinical Oncology Annual Meeting ,European Society ,Medical Oncology ,Medical Oncology Breast Cancer ,Advanced Breast ,New England Journal ,Medical Oncology Congress ,San Antonio Breast Cancer Symposium ,Practice Guidelines ,Published March ,Published April ,Vestre Viken Hospital Trust ,Neoadjuvant Treatment ,